TriSalus Life Sciences Warrant
TLSIW
7 hedge funds and large institutions have $1.23M invested in TriSalus Life Sciences Warrant in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
13% less funds holding
Funds holding: 8 → 7 (-1)
30% less capital invested
Capital invested by funds: $1.77M → $1.23M (-$537K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$741 |
| 2 |
Rockefeller Capital Management
New York
|
+$67 |
Top Sellers
TLSIW Hedge Fund Activity: Q1 2026 in Review
7 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences Warrant (TLSIW) for Q1 2026, worth a combined $1.23M — down 30% from $1.77M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of TLSIW and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Aristeia Capital, adding an estimated $741. The largest seller was Wolverine Asset Management, exiting entirely with an estimated $51.4K sold.
- 7 institutional investors held TriSalus Life Sciences Warrant (TLSIW) as of Q1 2026, down from 8 in Q4 2025.
- Funds reported $1.23M of TriSalus Life Sciences Warrant stock for Q1 2026, down 30% quarter-over-quarter.
- 1 fund opened new TriSalus Life Sciences Warrant positions in Q1 2026 and 2 closed out, a net change of -1 holder.
- The largest TriSalus Life Sciences Warrant buyer in Q1 2026 was Aristeia Capital, an estimated $741 added.
- The largest TriSalus Life Sciences Warrant seller in Q1 2026 was Wolverine Asset Management, an estimated $51.4K sold.
Based on aggregated 13F filings for Q1 2026.